The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

Your body is a collection of cells carrying thousands of genetic mistakes accrued over a lifetime—many harmless, some bad and ...

Researchers have identified many genes, known as oncogenes, that initiate and drive cancer when mutated. Although scientists have long speculated that mutations protecting against cancer also ...

Cancer risk in men depends on both genetics and lifestyle, with factors like smoking, diet, and exercise playing significant ...

Short-chain fatty acids influence gene regulation and chromatin accessibility, highlighting their role in colorectal cancer ...

Safety: Aspirin was well-tolerated, with no major safety concerns reported. The ASCOLT trial showed that aspirin did not ...

Dec. 23, 2024 — A research team has developed a groundbreaking technology that can treat colon cancer by converting cancer cells into a state resembling normal colon cells without killing them ...

Genetic testing is recommended for those with personal and family histories of several types of cancer — including pancreatic and breast cancer.

Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer: Thousand Oaks, California Monday, January 20 ...